The Immunity-enhanced group of breast cancer with relative low expression of ER, PR, HER2, basal cytokeratins and proliferation drivers might be less responsive to treatments with anti-estrogen, Herceptin and general chemotherapies, but may benefit more from the immunotherapies. The gene discussed is ESR1; the disease is breast carcinoma.